Compare SUZ & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUZ | HALO |
|---|---|---|
| Founded | 1924 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 12.0B |
| IPO Year | 2002 | 2001 |
| Metric | SUZ | HALO |
|---|---|---|
| Price | $8.98 | $130.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $12.38 | ★ $108.78 |
| AVG Volume (30 Days) | ★ 3.0M | 2.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.11 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $8.90 | $34.69 |
| Revenue Next Year | $15.03 | $11.65 |
| P/E Ratio | ★ $5.58 | $41.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.56 | $61.23 |
| 52 Week High | $11.54 | $128.94 |
| Indicator | SUZ | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 78.30 |
| Support Level | $8.09 | $105.27 |
| Resistance Level | $9.17 | N/A |
| Average True Range (ATR) | 0.21 | 3.32 |
| MACD | 0.07 | 1.02 |
| Stochastic Oscillator | 93.20 | 99.87 |
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.